Welcome to CDC stacks | Pneumococcal Infection among Children before Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Cambodia - 35555 | Emerging Infectious Diseases
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Pneumococcal Infection among Children before Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Cambodia
Filetype[PDF-904.33 KB]


Details:
No Related Documents.
You May Also Like:
  1. Invasive Streptococcus pneumoniae in Children, Malawi, 2004–2006
    Personal Author:
    Cornick, Jennifer E.; Everett, Dean B.; Broughton, Caroline; Denis, Brigitte B.; Banda, Daniel L.; Carrol, Enitan D.; Parry, Christopher M.;
    Published:
    Jun 2011
    Source:
    Emerg Infect Dis. 17(6):1107-1109.
    Description:
    Of 176 invasive Streptococcus pneumoniae isolates from children in Malawi, common serotypes were 1 (23%), 6A/B (18%), 14 (6%), and 23F (6%). Coverage with the 7-valent pneumococcal conjugate vaccine (PCV) was 39%; PCV10 and PCV13 increased coverage t...
    File Type:
    Filetype[PDF - 156.51 KB]
  2. Pneumococcal Meningitis in Adults after Introduction of PCV7 and PCV13, Israel, July 2009–June 20151
    Personal Author:
    Regev-Yochay, Gili; Reisenberg, Klaris; Katzir, Michal; Wiener-Well, Yonit; Rahav, Galia; Strahilevitz, Jacob; Istomin, Valery; Tsyba, Evgenia; Peretz, Avi; Khakshoor, Shirley; Dagan, Ron;
    Corporate Author:
    on behalf of the Israeli Adult Invasive Pneumococcal Disease Group
    Published:
    Jul 2018
    Source:
    Emerg Infect Dis. 24(7):1275-1284.
    Description:
    The indirect effect of pneumococcal conjugate vaccine on adult pneumococcal meningitis has not been thoroughly investigated. We present data from active surveillance on pneumococcal meningitis in adults in Israel occurring during July 2009-June 2015....
    File Type:
    Filetype[PDF - 1.12 MB]
  3. Incidence of Pneumococcal Pneumonia among Adults in Rural Thailand, 2006–2011: Implications for Pneumococcal Vaccine Considerations
    Personal Author:
    Piralam, Barameht; Tomczyk, Sara M.; Rhodes, Julia C.; Thamthitiwat, Somsak; Gregory, Christopher J.; Olsen, Sonja J.; Praphasiri, Prabda; Sawatwong, Pongpun; Naorat, Sathapana; Chantra, Somrak; Areerat, Peera; Hurst, Cameron P.; Moore, Matthew R.; Muangchana, Charung; Baggett, Henry C.;
    Published:
    Oct 26 2015
    Source:
    Am J Trop Med Hyg. 2015; 93(6):1140-1147.
    Description:
    The incidence of pneumococcal pneumonia among adults is a key driver for the cost-effectiveness of pneumococcal conjugate vaccine used among children. We sought to obtain more accurate incidence estimates among adults by including results of pneumoco...
    File Type:
    Filetype[PDF - 741.13 KB]
  4. Effects of Pneumococcal Conjugate Vaccine on Genotypic Penicillin Resistance and Serotype Changes, Japan, 2010–2017
    Personal Author:
    Ubukata, Kimiko; Takata, Misako; Morozumi, Miyuki; Chiba, Naoko; Wajima, Takeaki; Hanada, Shigeo; Shouji, Michi; Sakuma, Megumi; Iwata, Satoshi;
    Corporate Author:
    Invasive Pneumococcal Diseases Surveillance Study Group
    Published:
    Nov 2018
    Source:
    Emerg Infect Dis. 24(11):2010-2020.
    Description:
    To clarify year-to-year changes in capsular serotypes, resistance genotypes, and multilocus sequence types of Streptococcus pneumoniae, we compared isolates collected from patients with invasive pneumococcal disease before and after introductions of ...
    File Type:
    Filetype[PDF - 2.95 MB]
  5. Prevention of pneumococcal disease among infants and children: use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine : recommendations of the Advisory Committee on Immunization Practices (ACIP)
    Personal Author:
    Nuorti, J. Pekka; Whitney, Cynthia G.;
    Corporate Author:
    United States. Advisory Committee on Immunization Practices.. Centers for Disease Control and Prevention (U.S.). National Center for Immunization and Respiratory Diseases (U.S.). Division of Bacterial Diseases..
    Published:
    December 10, 2010
    Series:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 59, no. RR-11
    Description:
    "On February 24, 2010, a 13-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals Inc., marketed by Pfizer Inc.]) was licensed by the Food and Drug Administration (FDA) for prevention of invasive pneum...
    Status:
    current
    File Type:
    Filetype[PDF - 569.96 KB]